You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
回盛生物(300871.SZ):上半年公司投入研發費用3153.24萬元

格隆匯8月6日丨回盛生物(300871.SZ)在投資者關係中表示,公司持續加大研發和科技創新投入力度,聚焦新獸藥的開發,提升產品競爭力。2025年上半年,公司投入研發費用3,153.24萬元,較上年同期增加19.16%。公司加快新藥報批與轉產效率,持續推進新獸藥、比對類產品獲批。截至2025年6月30日,公司已取得19個新獸藥註冊證書,其中,上半年獲得4個新獸藥註冊證書,包括米氮平軟膏、恩康唑、恩康唑溶液及四季青提取散,公司已取得獸藥批準文號219個。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account